全文获取类型
收费全文 | 714篇 |
免费 | 28篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 27篇 |
妇产科学 | 11篇 |
基础医学 | 39篇 |
口腔科学 | 15篇 |
临床医学 | 48篇 |
内科学 | 183篇 |
皮肤病学 | 7篇 |
神经病学 | 44篇 |
特种医学 | 74篇 |
外科学 | 43篇 |
综合类 | 51篇 |
预防医学 | 20篇 |
药学 | 97篇 |
中国医学 | 1篇 |
肿瘤学 | 89篇 |
出版年
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 3篇 |
2017年 | 8篇 |
2016年 | 11篇 |
2015年 | 7篇 |
2014年 | 15篇 |
2013年 | 15篇 |
2012年 | 23篇 |
2011年 | 22篇 |
2010年 | 23篇 |
2009年 | 13篇 |
2008年 | 34篇 |
2007年 | 45篇 |
2006年 | 34篇 |
2005年 | 22篇 |
2004年 | 24篇 |
2003年 | 21篇 |
2002年 | 24篇 |
2001年 | 24篇 |
2000年 | 13篇 |
1999年 | 19篇 |
1998年 | 31篇 |
1997年 | 24篇 |
1996年 | 24篇 |
1995年 | 14篇 |
1994年 | 21篇 |
1993年 | 16篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 14篇 |
1989年 | 17篇 |
1988年 | 20篇 |
1987年 | 13篇 |
1986年 | 16篇 |
1985年 | 24篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1982年 | 12篇 |
1981年 | 7篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 4篇 |
1969年 | 2篇 |
排序方式: 共有750条查询结果,搜索用时 15 毫秒
1.
2.
3.
Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid. 总被引:1,自引:1,他引:0 下载免费PDF全文
D M Burger H Rosing C H ten Napel T Duyts P L Meenhorst J W Mulder C H Koks A Bult J H Beijnen 《Antimicrobial agents and chemotherapy》1994,38(12):2763-2767
A specific and sensitive radioimmunoassay for the determination of levels of zalcitabine in human plasma, urine, and cerebrospinal fluid has been developed. Commercially available radiolabel and antiserum (Sigma Chemicals) were used after dilution in assay buffer. Prior to the immunoassay, standard and patient samples were subjected to solid-phase extraction on silica columns in order to obtain purified samples. The lower limit of quantitation was determined to be 1 ng/ml. Intra- and interassay variations were less than 11% for a number of quality control samples of drug in plasma and urine. Results from parallelism studies with plasma and urine demonstrated that samples outside the standard range (1 to 30 ng/ml) could be diluted by blank plasma or assay buffer, respectively. A large number of related compounds and potentially coadministered drugs were tested for cross-reactivity. Stability tests showed that heat treatment for 30 min at 60 degrees C or storage for 1 month at -30 degrees C did not affect zalcitabine concentrations in plasma or urine. The radioimmunoassay with solid-phase extraction for sample cleanup discussed here has been successfully applied in a pharmacokinetic study of a single patient, demonstrating its applicability for clinical pharmacokinetic research with zalcitabine. 相似文献
4.
5.
6.
M Kaplan HJ Vreman C Hammerman C Leiter B Rudensky MG MacDonald DK Stevenson 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):455-457
The incidence (%) of hyperbilirubinemia (serum bilirubin ≥257 μmol/l) was similar in neonates with a combination of ABO incompatibility and glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (45%), with ABO incompatibility (54%) or G-6-PD deficiency (37%), alone (ns). Carboxyhemoglobin values, corrected for inspired CO, were similarly elevated in all three groups (0.87 ± 0.32%, 0.82 ± 0.29%, 0.76 ± 0.18%, respectively, ns), but correlated with bilirubin only in those with ABO incompatibility alone. ABO-incompatible/G-6-PD-deficient neonates, compared with those with either condition alone, are not at increased risk for hemolysis or hyperbilirubinemia. 相似文献
7.
Long-term anatomic fate of coronary-artery bypass grafts and functional status of patients five years after operation. 总被引:3,自引:0,他引:3
S F Seides J S Borer K M Kent D R Rosing C L McIntosh S E Epstein 《The New England journal of medicine》1978,298(22):1213-1217
To assess long-term results, coronary and graft angiography was performed 53 to 84 months after operation in 22 of 30 consecutive patients who had undergone coronary-artery bypass grafting before 1973, and who had at least one graft patent at an early (three to nine months) postoperative study. Of the 33 grafts, 31 were patent at late study. All patients had severe symptoms before operation. Of 16 who became asymptomatic early after operation, angina pectoris later redeveloped in 11. Progression of disease in ungrafted vessels accounted for symptomatic deterioration in nine of these 11 patients. We conclude that most grafts patent several months after operation remain so for at least 4 1/2 years, and that although most patients improve symptomatically after operation, symptomatic deterioration is common in the succeeding years and is most often due to progression of disease in ungrafted vessels. 相似文献
8.
9.
Renske M.T. ten Ham Merel van Nuland Rick A. Vreman Laurens G. de Graaf Hilde Rosing André M. Bergman Alwin D.R. Huitema Jos H. Beijnen Anke M. Hövels 《Value in health》2021,24(1):121-128
ObjectivesAbiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome is associated with plasma trough concentrations (Cmin) of abiraterone. Patients with a plasma Cmin below the target of 8.4 ng/mL may benefit from treatment optimization by dose increase or concomitant intake with food. This study aims to investigate the cost-effectiveness of monitoring abiraterone Cmin in patients with mCRPC.MethodsA Markov model was built with health states progression-free survival, progressed disease, and death. The benefits of monitoring abiraterone Cmin followed by a dose increase or food intervention were modeled via a difference in the percentage of patients achieving adequate Cmin taking a healthcare payer perspective. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainties and their impac to the incremental cost-effectiveness ratio (ICER).ResultsMonitoring abiraterone followed by a dose increase resulted in 0.149 incremental quality-adjusted life-years (QALYs) with €22 145 incremental costs and an ICER of €177 821/QALY. The food intervention assumed equal effects and estimated incremental costs of €7599, resulting in an ICER of €61 019/QALY. The likelihoods of therapeutic drug monitoring (TDM) with a dose increase or food intervention being cost-effective were 8.04%and 81.9%, respectively.ConclusionsMonitoring abiraterone followed by a dose increase is not cost-effective in patients with mCRPC from a healthcare payer perspective. Monitoring in combination with a food intervention is likely to be cost-effective. This cost-effectiveness assessment may assist decision making in future integration of abiraterone TDM followed by a food intervention into standard abiraterone acetate treatment practices of mCRPC patients. 相似文献
10.
Anorexia nervosa (AN) is a serious life-threatening illness that typically has its onset during the adolescent years. Evidence regarding the optimal treatment of AN in children and teenagers is growing; however, much remains unknown. Although current treatment approaches vary in Canada and elsewhere, the evidence to date indicates that family-based treatment (FBT) is the most effective treatment for children and teenagers with AN. A key component of the FBT model is that the parents are given the responsibility to return their child to physical health and ensure full weight restoration. An understanding of the basic principles and philosophy underlying FBT allows the physician to initiate elements of this evidence-based intervention to young patients with AN and their families. 相似文献